NCT02716220 - Pre-market Study of the DREAMS 2G Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-III) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

August 31, 2019

Conditions

Coronary Artery DiseaseCoronary Artery Stenosis

Interventions

DEVICE

Percutaneous Coronary Intervention

Implanttaion fo the DREAMS 2G Scaffold

Trial Locations (8)

Interventional Cardiology Middelheim Hospital (ZNA Middelheim), Antwerp

Universitätsklinik Inselspitalspital Bern, Bern

Vivantes Klinikum Friederichshain,, Berlin

Universitätsmedizin Rostock, Rostock

Segeberger Kliniken GmbH, Bad Segeberg

Städtische Kliniken Neuss, Neuss

Amper Kliniken AG, Dachau

Thoraxcenter, Erasmus Medical Center, Rotterdam